FDA approves Brytly eye drops for nonprescription redness relief
FDA approved apraclonidine 0.125% eye drops for redness from minor irritation in adults and children ages 12 and older.
What the record says
The October 16 announcement names Alcon’s Brytly as the first nonprescription eye drop containing apraclonidine. The approval concerns redness relief, while higher-concentration prescription products have different uses.
Source details and supporting locations.
Practical next step
Read the complete Drug Facts label. FDA says to remove contact lenses before use and wait at least 10 minutes before replacing them; do not use the product more than twice daily.
Limits and what is not established
FDA advises stopping use and asking a doctor about eye pain, vision changes, persistent redness or irritation, worsening symptoms, or symptoms lasting more than three days. Approval does not establish retail availability, pricing or suitability for a particular person.
Sources checked October 17, 2026. Later notices may change instructions or arrangements.
Original sources
U.S. Food and Drug Administration: original information